QUIDEL CORP: directors' dealings · United States · SEC (Form 4)

About QUIDEL CORP

QuidelOrtho Corporation (Nasdaq: QDEL) is a U.S.-listed company traded on the NASDAQ market in the United States. The company was created in 2022 through the combination of Quidel and Ortho Clinical Diagnostics, while Quidel’s operating history dates back to 1979. Its world headquarters is in San Diego, California, which places the company in one of the most established U.S. medtech and diagnostics hubs. For investors, QDEL is best viewed as a diagnostic-testing franchise with defensive end markets, but one that remains exposed to respiratory seasonality, hospital utilization trends, and laboratory spending patterns. QuidelOrtho develops and commercializes in vitro diagnostic solutions spanning point-of-care testing, clinical laboratories, and transfusion medicine. Its core portfolio includes the SOFIA platform for automated point-of-care immunoassays, QuickVue rapid lateral-flow tests, the TRIAGE system for quick diagnostic results at the point of care, and the VITROS and ORTHO product families used in laboratory testing and immunohematology. The company also offers molecular testing solutions and related reagents. According to company materials, it serves customers in more than 140 countries and territories, giving it a broad commercial footprint and meaningful diversification across healthcare settings and geographies. That reach is strategically important because the business is not dependent on a single product line or a single end market. From a competitive standpoint, QuidelOrtho occupies a strong niche in rapid diagnostics and laboratory workflow solutions. Its value proposition is built around speed, accuracy, automation, and ease of use, which are critical attributes for healthcare providers facing cost and efficiency pressures. The company competes against larger diagnostics players, but its product depth across respiratory, women’s health, general health, lab, and transfusion applications supports a differentiated position. Its installed base and international distribution network further reinforce the franchise. Recent developments have been important for the investment case. In 2025 and early 2026, management highlighted a softer respiratory season, slower distributor sales in China, and disruption linked to Middle East conflict, all of which weighed on results and guidance. At the same time, the company has been taking cost and execution actions to support margin and cash flow. A notable strategic move came in April 2026, when QuidelOrtho acquired LEX Diagnostics for approximately $100 million, a transaction intended to accelerate growth in point-of-care molecular diagnostics. For French, Belgian, and Swiss investors, QDEL represents a U.S.-listed diagnostics company with a credible global franchise, but one where near-term results can be volatile and where product launches and strategic execution matter materially.